51 - Transitioning to Phase 2 - Efficacy Focus (S4E6)

All right, let's dive into drug development today,
and specifically when it jumps from phase one
to phase two trials. I know a lot of you have
been curious about, well, how does it shift from
like, is this safe, to does this thing actually
work? So let's try and break it down. Sort of
like, imagine you have a new drug, it's promising,
passed all the safety tests. but now we gotta
see if it delivers. Yeah, that's right. It's
a little bit like graduating from basic training
to actually going out into the field. Okay, so
before we jump ahead to phase two, let's just
do a quick recap of what phase one is all about.
It's all about safety first, right? Exactly.
Phase one is really like a meticulous detective
just investigating every nook and cranny. We're
looking at tolerability, side effects, and how
the drug moves. throughout the body. Absorption,
distribution, metabolism, and excretion, or ADME
for short. Researchers can actually track the
drug's journey using radio labeled molecules.
So it's like giving the drug a tiny little GPS
tracker. That's wild. So phase one will give
us a detailed itinerary for the drug and help
determine the safest and most effective dose
for future studies. So in comes phase two, and
that's where we shift the focus to efficacy.
What actually changes, like in terms of the study
goals and design? The main difference is that
we're actually now directly assessing the drug's
impact on the targeted disease. Instead of just,
you know, a small group of volunteers, phase
two trials usually have a larger, more diverse
group of patients. Gotcha. So that gives us a
much better picture of how the drug performs
in more like a real world setting. That makes
sense. We need a bigger sample size to really
get a clearer picture of its efficacy. Exactly.
But how do we even measure if a drug is actually
doing its job? Right. the metrics or the yardsticks
that we use. Right. Well, that's where we have
these efficacy endpoints come in. And these are
very specific, measurable outcomes that reflect
the desired effect of the drug. OK. So imagine
if you're trying to measure the effectiveness
of like a new fertilizer. You wouldn't just look
at how tall the plants grow. You'd want to also
want to measure yield and quality and resistance
to pests, those kind of things. So the efficacy
endpoints are like choosing the right measuring
tool for the job. You need the right yardstick
to actually assess whether the drug is hitting
its target. Precisely. Yeah. The endpoints will
definitely change and vary depending on the disease
and how the drug works. Like for example, in
a trial for a new diabetes drug. Okay. A really
key efficacy endpoint might be reduction in blood
sugar levels. Makes sense. But in a cancer trial,
it might be tumor shrinkage or even increase
in survival time. Okay, so we've defined these
endpoints and we're tracking them during phase
two. Yeah. Can we get any hints about if the
drug is working before the whole study is done?
Like are there any little indicators, I guess,
sneak peeks? Yes, there can be. Oh really? We
call these early indicators of benefit. Right.
And they can offer really valuable inside. You
know, it's important to interpret them cautiously.
Sometimes we observe trends in the data as it
comes in. For example, let's say we're seeing
a steady decrease in blood pressure in a hypertension
trial. Well, that could be a good early sign.
It's like watching a puzzle kind of come together
piece by piece. But like you said, you don't
want to jump to conclusions too early. Exactly.
Exactly. We need to let the data mature a bit
and see if the early trends hold up. Exactly.
In addition to these trends, another really strong
early indicator can be what are called biomarkers.
And these are specific biological measures that
can indicate a response to the drug at a molecular
level. OK. So if a drug is, let's say it's designed
to block a protein. we might actually measure
the levels of that protein in the blood to see
if they decrease after the treatment, right?
Exactly. So it's like a deeper level of understanding
beyond just the clinical outcomes. Exactly, exactly.
Now to give you a real world example, let's look
at a phase two study of a drug called kinagliflozin,
and this is used to treat type 2 diabetes. Okay.
The researchers were looking at its effect on
HbA1c levels, which is a measure of long -term
blood sugar control. And what did they find?
Well, the study showed that canagloflozin significantly
reduced HbA1c levels compared to the placebo.
And this early success in phase two was a huge
factor in the drug eventually being approved
for more widespread use. Wow. So it was like
a stepping stone, this phase two study. Absolutely.
Absolutely. It's amazing to see these trials
like connect the dots between lab research and
real world impact. Absolutely. But it's important
to remember that these trials aren't done in
isolation. There's a really solid regulatory
framework in place to ensure safety and scientific
rigor. So who are the key players kind of overseeing
everything? Right. So organizations like the
FDA here in the US and the ICH internationally,
they set very strict guidelines and standards
for every stage of drug development. OK. So they're
kind of like the guardians of patient safety.
making sure that the data from these trials is
reliable and trustworthy. That's good to know.
Gives me peace of mind that there's a system
in place to ensure that scientific progress and
patient well -being are both moving forward together.
Absolutely. And that balance is at the heart
of. everything we do in drug development. This
has been really insightful. We've covered so
much. Yeah. The shift from safety to efficacy,
the importance of endpoints, early indicators,
the whole regulatory landscape. And we've really
only just scratched the surface. I mean, there's
so much more to dive into within each of those
topics. Absolutely. But for now, we'll leave
you with this. As we kind of go further into
this world of drug development, what questions
are coming to mind for you? What would make you
feel confident in the results? of a phase two
study. Just keep those questions in your mind
as we as we keep exploring. Yeah. Yeah. Yeah,
it's fascinating how those questions just sort
of bubble up, you know, as we peel back the layers
of drug development. It's like, you know, when
you go into a really dense forest, the deeper
you get, the more you realize how much more there
is to discover. You're so right. And those questions
about what gives us confidence in a phase two
study. I mean, they're huge because these trials
aren't just about getting data. It's about making
decisions, big decisions that could impact so
many patients. Exactly. A successful phase two
trial. can really set the stage for larger, more
definitive phase three studies, which then get
us closer to those potentially life -changing
treatments. But one that's, let's say, a little
less conclusive, a phase two, might actually
lead to adjustments, maybe even additional studies,
or sometimes even a decision to just halt development
altogether. So what would be some of those warning
signs or red flags that would make researchers
think twice about going forward after a phase
two? Well, I think one of the big concerns would
be unexpected or severe side effects. OK. Remember,
while safety is the primary focus in phase one,
in phase two, we're testing the drug on a larger,
more diverse group of patients. Right. So this
can uncover rarer side effects that didn't really
show up in the earlier phases. I see. So we're
widening the scope and catching things we might
not have seen before. Right. Exactly. Another
potential concern is if the drug doesn't really
show a statistically significant effect on the
chosen endpoints. OK. Now, we talked about efficacy
endpoints before, but it's really worth emphasizing
that these endpoints need to really demonstrate
a true and meaningful difference between the
drug and either a placebo or even the standard
treatment. So it's not just about the drug showing
any effect at all. It needs to really beat the
alternative. Exactly. It needs to be statistically
significant. And that's really where rigorous
statistical analysis comes in, because it helps
us determine if what we see is really because
of the drug itself or just random chance. Because
there's always a chance of fluke results even
in a well -controlled study, right? Oh, absolutely.
Statistical analysis helps us sort of separate
the signal from the noise so that we can be sure
our conclusions are actually evidence -based.
Okay, so let's say the phase two trial is, you
know, showing good things, drug is safe, well
tolerated, it has a good statistically significant
effect. Does that guarantee a smooth ride into
phase three? Not necessarily. There are other
things that the researchers and the regulatory
agencies are looking at. For example, they might
look at how big is that effect? Is it clinically
meaningful? Does it really translate into real
world benefits for patients? So for example,
if a blood pressure medication shows a statistically
significant decrease, but it's like minuscule,
it might not actually make a difference in someone's
overall health. Exactly. We need to see a strong
enough effect. to really justify moving to a
big and expensive phase three trial. Right. So
it's like this balance between the science and
just, you know, practicality. Absolutely. And
another factor that we look at is, is there already
a good treatment for this condition? OK. If so,
this new drug needs to show us something really
special. It's not enough to just work. It's got
to work better. Exactly. It's about really pushing
those boundaries of medical innovation, you know,
offering patients the best options we can. And
I imagine the regulatory agencies, like you mentioned
before, FDA, ICH, they're really weighing in
on these decisions too, right? Absolutely. They
look over all the data from these phase two trials
with a fine -toothed comb. Wow. They look at
everything, safety, efficacy. Was the study designed
well? Was the statistical analysis done correctly?
You know, they want to be really confident that
the drug is a good candidate before they give
the green light to phase three. So it's a rigorous
process, a lot of scrutiny at every level, which
is good, makes me feel better. Knowing patient
safety and scientific integrity are at the forefront
of all that. Oh, absolutely. Okay, so we talked
about the trial going well, what if it doesn't
meet expectations? Is that like game over for
the drug? Not always, sometimes. A phase two
trial that doesn't, you know, totally hit the
mark, it might lead to some adjustments or refinements.
So researchers might explore different doses
or test it out on different patient groups or
maybe even combine the drug with another existing
treatment. So there's no one straight path. There
could be detours and like... unexpected twists
and turns. That's science, right. And sometimes
those detours can lead to some really surprising
findings, you know, new paths of research. That's
what makes this whole area so fascinating. It's
constant learning, adapting and refining what
we know. Exactly. And even if that particular
drug doesn't, you know, ultimately get to market,
the knowledge we gain from those early trials.
That's gold. It can inform so much future research,
pave the way for all kinds of new discoveries.
It's like each trial, whether it's a win or a
setback, it's all adding to that bigger picture
of medical advancement. Yeah, that's a great
way to put it. And it's that collective knowledge
built on so many trials and experiments. That's
what really drives progress in medicine and improves
people's lives all over the world. Speaking of
those trials, I'm curious about the people in
them. What would motivate someone to be part
of? A phase two study. That's a great question.
You know, the motivations are all over the map.
OK. Some people are really driven by a desire
to just help move science forward. Wow. They
see it as a way to be a part of something bigger
than themselves, you know, potentially help people
down the road. That's incredibly altruistic.
It is. It takes a very special kind of person
to step up like that, be on the front lines of
medical research. Yeah. And for some people,
it's... it's something a bit more personal. They
might be dealing with an illness and hoping that
this experimental treatment could help them,
maybe even cure them. So there's this element
of hope and also just wanting to make a difference.
Absolutely. And I think it's really important
to keep in mind that that joining a clinical
trial, that's a big decision. And we owe a ton
of gratitude to the people who volunteer. What
they do is invaluable. For sure. You mentioned
earlier that these phase two trials, they often
involve patients with this specific condition.
How are those patients recruited? And how do
you make sure that the group of people in the
study, they're a good representation of the broader
patient population? Yeah, that's a super important
part of designing a trial. And it's something
that the researchers think very carefully about.
Patient recruitment, that usually involves working
with health care providers, patient advocacy
groups, and even online platforms. It's about
reaching as many people as possible. And to make
sure that that group represents the the larger
patient population, researchers set up very specific
inclusion and exclusion criteria. And these criteria,
you know, they really define the characteristics
of who's eligible to be in the trial. So like
for a trial testing a new heart medication, the
inclusion criteria might be things like age,
medical history, how severe the condition is.
Exactly, and the exclusion criteria that might...
you know, rule out people with certain other
health problems or maybe people who are taking
medications that could interfere with the study
drug. It's all about getting a really well -defined
study group so that the researchers can draw
good conclusions about, you know, is it safe?
Does it work? Precisely. And that careful selection
process, that's a huge part of making sure the
results are really reliable and scientifically
sound. It's really amazing how much planning
and thought goes into every detail of these studies.
It's just incredible, the dedication and expertise
of the research teams. It is. And it's that commitment
to getting things right that gives us confidence
in the data that comes out of these trials and
ultimately helps us move the field of medicine
forward. Well, I feel like we've covered a lot
here. We talked about phase two trials of people
who take part in them. We have. And all the different
factors. So what are some of the emerging trends
or challenges that you're seeing right now in
the world of phase two research? Well, one really
exciting trend is the rise of personalized medicine.
As we learn more and more about the genes and
molecules involved in disease, we're actually
getting closer to tailoring treatments to each
individual. So instead of one size fits all,
we're developing drugs that are like laser focused.
Exactly. They target those specific pathways
or mutations that are really driving that person's
illness. And phase two trials, they're playing
a key role in this whole shift. Gotcha. They
let us test these really targeted therapies on
these carefully selected groups of patients and
then identify who's most likely to benefit. That's
wild. It's like medicine will become as unique
as each person. It really is. And although there's
still a lot of challenges to overcome, the potential
here is huge. For sure. It's so exciting to think
about the possibilities. Now, besides personalized
medicine, what else is shaping the phase two
research landscape? Well, another major development
is technology. I mean, we're seeing new tools
and platforms everywhere, you know, for collecting
and analyzing data, improving recruitment, even
monitoring patients remotely. So it's making
the process more efficient, more streamlined.
Exactly. And one area where technology is really
having a big impact is in the analysis of big
data. I mean, phase two trials, they generate
a mountain of information. So we have these sophisticated
algorithms, machine learning tools, and they're
helping us get these incredible insights from
the data. Like a super detective helping us find
clues. Yeah, a great analogy. And these insights,
they can help us fine tune our trial designs,
identify potential biomarkers. I mean, we can
even predict which patients are most likely to
respond to a specific treatment. It's amazing
how technology is changing how we do research
and develop new therapies. Yeah. But with all
this progress, there's got to be some new challenges
too, right? Oh, for sure. One of the biggest
challenges is just making sure all these fancy
tools are being used responsibly. We need to
think about patient privacy, data security, and
even the potential for bias that can creep into
these algorithms. It's not just about having
the technology. It's about using it wisely. Exactly.
And another challenge is, well, just keeping
up. The field is changing so fast. researchers
and regulatory agencies have to be on their toes
to make sure trials are designed and conducted
to the absolute highest standards. It's allowed
to keep up with a lot of moving parts. It is,
but that's what makes it so interesting. There's
always something new to learn. The possibility
for a breakthrough is always right around the
corner. Well, this has been a fascinating conversation.
It has. I feel like we've explored so much about
phase two trials. Yeah. The importance of the
efficacy endpoints, early signs of benefit, the
trends, the challenges. We've really only just
scratched the surface, but hopefully this conversation
has given you a better understanding of how important
phase two is in the drug development process.
Absolutely. Before we wrap things up, I want
to go back to something you said earlier about
patient participation. Yeah. What advice would
you give to someone who's thinking about volunteering
for a phase two study? Well, I would say, first
of all, it's a very personal decision. There's
no right or wrong answer. It's really important
to weigh the potential benefits and the risks
very carefully and to talk to your doctor, talk
about any concerns you have. So it's all about
making an informed decision that feels right
for you. Exactly. And I would also add that,
you know, taking part in these trials, it's a
really selfless act. It contributes to medical
knowledge and can potentially help so many others.
It's a real gift. It is. And to everyone who
has participated or is considering it, thank
you. You are the unsung heroes of medical progress.
Well said. Now, before we give our listeners
a final thought, I'm curious about something.
We've been talking about the different things
that influence the decision to take a drug from
phase two to phase three, but who ultimately
makes that call? That's a great question, and
the answer is it's a team effort. OK. You have
the research team, the pharmaceutical company
that's sponsoring the trial, and of course, the
regulatory agencies. So it's not just one person
in a room making that decision. Exactly. It's
a very thorough process, a lot of back and forth,
evaluating the data, considering the benefits
and risks, and really looking at all the regulations.
It's just a good reminder that drug development
is complex and very regulated. and for good reason.
Absolutely. And that careful step -by -step approach,
that's what makes sure the treatments that ultimately
get to patients are safe, effective, and can
truly change lives. This has been a really insightful
conversation. Thank you for being here today.
It's been my pleasure. Yeah, it's really something,
you know, how much consideration and how many
different viewpoints go into making that final
decision. It really shows how collaborative drug
development really is. It is. It's definitely
not a solo mission. It takes, you know, experts
from all sorts of fields. Right. Scientists,
clinicians, statisticians, regulatory folks.
I mean, the list goes on. It's like a huge orchestra.
Each section is playing this crucial part to
create a harmonious outcome. I love that analogy.
And you're right. That harmony is so important.
Because in the end, it's all about getting safe
and effective treatments to people who need them.
And that kind of brings me to something I've
been thinking about throughout our conversation.
With all the research, all the testing, all the
scrutiny that goes into drug development, how
do we find that sweet spot between scientific
progress and the very real needs of patients,
especially when sometimes those needs are urgent?
That's a really deep question. And it's something
everyone in this field grapples with. I mean,
on one hand, we have a responsibility to thoroughly
evaluate new therapies, make sure they're safe,
make sure they work. You know, we don't want
to be putting patients at risk or giving them
false hope. Absolutely. It's about being careful,
responsible, and making sure medical innovation
is moving forward in the right way. Exactly.
But at the same time, we know that for some people,
time is not a luxury they have. They're dealing
with you know, serious conditions, maybe even
life threatening, and there might not be many
treatment options out there. So the idea of a
new therapy, even if it's still being developed,
that can be a real beacon of hope. It's a delicate
balance, isn't it? Like you need the science,
the rigor, but you also have to acknowledge the
human side of things, the need for healing, for
hope. It really is. And finding that balance
often comes down to open communication between
researchers, regulatory agencies, patient advocacy
groups, and most importantly, the patients themselves.
It's a conversation, a dialogue, not just someone
telling you what to do. It's recognizing the
complexity and working together to find the best
way forward. Absolutely. And that often means
exploring things like accelerated approval pathways
for drugs that are addressing really serious
life -threatening conditions while still making
making sure that patient safety is the top priority.
So it's about speeding things up when you can,
but never cutting corners. Exactly. And it's
always evolving as we learn more about diseases,
develop new technologies, and refine our understanding
of what it takes to actually bring safe and effective
treatments to the world. It's a constant process
of learning and improvement. It is. And that's
what makes this field so exciting. There's always
something new to learn, and the potential for
groundbreaking discoveries is always there. This
has been an incredible journey, really eye -opening,
you know, looking at drug development from those
early steps in phase one to those critical decisions
made in phase two and beyond. We've just scratched
the surface, but I hope our conversation has
given you a little glimpse into how complex it
is, the challenges involved, and most importantly,
the incredible potential of this whole field.
It really has for me, too. And for our listeners
out there, as we wrap up our deep dive into this
transition from phase one to phase two, What
sticks with you? What new things have you learned?
Or what questions are still swirling around in
your head? Keep thinking about those things,
you know, as you continue to explore this amazing
world of medicine and scientific discovery. And
remember, every breakthrough, every new treatment,
it all started with a question, a spark of curiosity,
and that dedication to pushing the boundaries
of what's possible.